Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement
Sarah P. Blagden(Churchill Hospital), A. Yiangou(Cancer Research Horizons), Sean Buckland(Pfizer (United Kingdom)), Aoife Regan(NIHR CRUK Experimental Cancer Medicine Centre), Ilaria Mirabile(NIHR CRUK Experimental Cancer Medicine Centre), Helen Campbell(University of Oxford), Will Navaie(Greater London Authority), Marivic Ricamara, Francesca Schiavone(MRC Clinical Trials Unit at UCL), Maria Antonietta Cerone(Cancer Research Horizons), F. Maignen(National Institute for Health and Care Excellence), Catherine Blewett(Greater London Authority), Serban Ghiorghiu(AstraZeneca (United Kingdom)), Pamela Kearns(National Institute for Health and Care Research), Claire Potter(Cancer Research UK Clinical Trials Unit), Sarah Halford(Cancer Research Horizons), Matthew R. Sydes(MRC Clinical Trials Unit at UCL), Glen Clack(University of Sheffield), Alison M. Cooper(Association of the British Pharmaceutical Industry), Kirsty Wydenbach, Anna Lawson(Cancer Research UK Clinical Trials Unit), Natalie Cook(The Christie NHS Foundation Trust), Sarah Pearson(University of Oxford), Emma T. Lowe(Department of Health and Social Care), Louise Brown(North Manchester General Hospital), Charles G. Weller(NHS Research Scotland), Debbie Keatley(CRUK Lung Cancer Centre of Excellence), Dipak Patel(Sheffield Teaching Hospitals NHS Foundation Trust), Rubina Ahmed(Cancer Research Horizons), Andrew Johnston(Newcastle upon Tyne Hospitals NHS Foundation Trust), Leeza Osipenko(National Institute for Health and Care Excellence), Jacqueline Mathews(NIHR Research Delivery Network), Wendy Fisher(Thermo Fisher Scientific (United Kingdom)), Alex Morozov(Pfizer (United States)), H Hughes(Cardiff and Vale University Health Board), Julie Silvester(Cancer Research Horizons), Stephanie Ellis(Greater London Authority), Joanne Rodger(NHS Research Scotland), Gurcharan K. Sandhu(NIHR CRUK Experimental Cancer Medicine Centre), Sue Bailey(Bristol-Myers Squibb (United Kingdom)), Christiane Abouzeid(BioIndustry Association), Lucinda Billingham(University Hospitals Birmingham NHS Foundation Trust), Carly Ringrose(University Hospital Southampton NHS Foundation Trust), Abeer M. Shaaban(Queen Elizabeth Hospital Birmingham)
Cited by 44
Related Papers
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|604
Mitomycin, Ifosfamide, and Cisplatin in Unresectable Non–Small-Cell Lung Cancer: Effects on Survival and Quality of Life
|Journal of Clinical Oncology|1999|449
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
|Journal of Clinical Oncology|2015|419